Motif Bio PLC CEO to Present at BIO 2016
01 Giugno 2016 - 8:01AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
01 June 2016
1 June 2016
Motif Bio plc
("Motif Bio" or the "Company")
CEO Graham Lumsden presenting at BIO 2016
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that CEO Graham Lumsden has been invited to present at BIO 2016
which is being held at the Moscone Center, 747 Howard Street, San
Francisco from June 6-9 2016.
The presentation will provide information on the progress of its
clinical lead antibiotic, iclaprim, into pivotal phase III trials
and will be held in presentation room 1 on Monday June 6 commencing
at 2.45pm.
The BIO convention brings together over 15,000 biotechnology and
pharma leaders, covering a wide spectrum of life sciences areas
including drug discovery, bio-manufacturing, genomics and more.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Walbrook PR Ltd +44 (0)20 7933 8780 or motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company,
specialising in the development of novel antibiotics that are
designed to be effective against serious and life-threatening
infections caused by multi-drug resistant bacteria. Our lead
product candidate, iclaprim, is being developed for the treatment
of the most common and serious bacterial infections such as acute
bacterial skin and skin structure infections (ABSSSI) and hospital
acquired bacterial pneumonia (HABP), including those caused by
resistant strains such as MRSA (methicillin-resistant
Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on
track to be completed in 2017 and if approved, iclaprim could be
ready for commercialization in 2018. The Company is in discussions
with pharmaceutical companies and universities to build a pipeline
of innovative antibiotics targeting Gram-positive and Gram-negative
bacteria. For additional information about Motif Bio please visit
www.motifbio.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKSFDFPKEFF
(END) Dow Jones Newswires
June 01, 2016 02:01 ET (06:01 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024